[Asia Economy Reporter Yoo Hyun-seok] Daehan New Pharm announced on the 11th through a public disclosure that it achieved a cumulative operating profit of 19.7 billion KRW (operating profit margin 17%) in the third quarter, marking a 22% increase compared to the same period last year. Sales rose 15% to 113.8 billion KRW, and net profit for the period was recorded at 6.3 billion KRW.
Quarterly performance also maintained its growth trend. Operating profit in the third quarter reached 7.4 billion KRW, up 40% from the same period last year. Sales also increased by 23% to 39.5 billion KRW.
Sales rose across the entire product range. Daehan New Pharm launched 'Fine S Tablets,' a cold and allergic rhinitis medication with bromelain as the main ingredient, and expanded sales by releasing 'Luchion Tablets,' containing glutathione, well known for its use in Baekok injections.
Additionally, Daehan New Pharm is known to be actively engaged in research and development despite the COVID-19 situation. By continuously strengthening distribution structure improvements and strategic risk management, the company was able to enhance overall performance.
A Daehan New Pharm official stated, “Steady sales were generated from key core product groups, and thanks to the efficient management system established in advance, we have continued stable growth despite the COVID-19 crisis. We will further maximize performance through intensified research and development as well as thorough distribution and management control.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
